Biomedtech News

Great article about Abivax : what makes it a unique candidate to treat Covid-19

December 2, 2020

In addition to its exciting results in ulcerative colitis, Abivax's ABX 464 has shown antiviral, anti-inflammatory and tissue repair properties in COVID-19 clinical trials.

ALSO TO BE DISCOVERED

December 1, 2020

Abivax completes recruitment of ABX464 phase 2b induction study in ulcerative colitis

November 17, 2020

Abivax receives “Best Technology Award” at the European Mediscience Awards 2020

October 29, 2020

Abivax announces the success of its oversubscribed capital increase

October 13, 2020

Abivax secures € 15M non-dilutive financing from Kreos Capital

October 12, 2020

CARMAT is granted € 13M in national innovation funding to conduct the EFICAS study in France

September 25, 2020

Abivax presents first-half 2020 financial results and operations update

September 15, 2020

Abivax Turns Away Suitors as Lead Drug Starts Covid-19 Tests

September 2, 2020

Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2A maintenance study

July 31, 2020

MEDEOR, Truffle Capital's new BioMedTech Fund, qualified by institutional investors through the Tibi committee

July 2, 2020

Abivax treats first patient in Phase 2B/3 ABX464 Covid-19 clinical trial